Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. AnaptysBio's Pre-Tax Income for the
three
months ended in Dec. 2024 was $-21.79 Mil. AnaptysBio's Revenue for the
three
months ended in Dec. 2024 was $43.11 Mil. Therefore, AnaptysBio's pretax margin for the quarter that ended in Dec. 2024 was -50.54%.
The historical rank and industry rank for AnaptysBio's Pretax Margin % or its related term are showing as below:
ANAB'
s Pretax Margin % Range Over the Past 10 Years
Min: -1251.09 Med: -229.9 Max: -25.53
Current: -159.1
ANAB's Pretax Margin % is ranked worse than 53.27% of 995
companies
in the Biotechnology industry
Industry Median: -127.47
vs ANAB: -159.10
AnaptysBio Pretax Margin % Historical Data
The historical data trend for AnaptysBio's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of AnaptysBio's Pretax Margin %
For the Biotechnology subindustry, AnaptysBio's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AnaptysBio's Pretax Margin % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AnaptysBio's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where AnaptysBio's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AnaptysBio (NAS:ANAB) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
AnaptysBio Pretax Margin % Related Terms
Thank you for viewing the detailed overview of AnaptysBio's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ANAB has been successfully added to your 